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Abstract Prohormone convertases (PCs) 1 and 2 are thought to
mediate the proteolytic cleavage of many peptide precursors.
Endogenous inhibitors of both PC1 and PC2 have now been
identified; the 7B2 protein is a nanomolar inhibitor of PC2, while
the novel protein proSAAS was recently reported to be a
micromolar inhibitor of PC1 [Fricker et al. (2000) J. Neurosci.
20, 639^648]. We here report evidence that 7B2 and proSAAS
exhibit several elements of structural and functional homology.
Firstly, 26 kDa human, mouse and rat proSAAS, like all
vertebrate 7B2s, contain a proline-rich sequence within the first
half of the molecule and also contain a C-terminal 40 residue
peptide (SAAS CT peptide) separated from the remainder of the
protein by a furin consensus sequence. The SAAS CT peptide
contains the precise sequence of a hexapeptide previously
identified by combinatorial peptide library screening as a potent
inhibitor of PC1, and the vast majority of the inhibitory potency
of proSAAS can be attributed to this hexapeptide. Further, like
the 7B2 CT peptide, SAAS CT-derived peptides represent tight-
binding competitive convertase inhibitors with nanomolar poten-
cies. Lastly, recombinant PC1 is able to cleave the proSAAS CT
peptide to a product with a mass consistent with cleavage
following the inhibitory hexapeptide. Taken together, our results
indicate that proSAAS and 7B2 may comprise two members of a
functionally homologous family of convertase inhibitor proteins.
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1. Introduction
The prohormone convertases (PCs) are a family of eukary-
otic subtilisins thought to be involved in the synthesis of a
wide variety of secreted proteins (reviewed in [1]). Certain of
these enzymes, such as furin, are expressed ubiquitously, while
other members of the family, such as PC1 and PC2, are found
primarily in neuroendocrine tissues, where they accomplish
the biosynthetic cleavage of peptide hormone precursors
such as proinsulin and proopiomelanocortin (reviewed in [1]).
Most proteinases are physiologically controlled by endoge-
nous inhibitor systems. However, until this year, only one
natural inhibitor of a member of the eukaryotic subtilisins
was known, the neuroendocrine protein 7B2, which contains
a 31 residue peptide with highly potent and speci¢c inhibitory
activity against PC2 (reviewed in [2]). Recently Fricker et al.
[3] identi¢ed a new neuroendocrine protein known as pro-
SAAS, which was shown to inhibit PC1 with micromolar in-
hibitory potency. In this report, we present evidence to sup-
port the notion of structural and functional similarities
between 7B2 and proSAAS and we identify the PC1-inhibi-
tory hexapeptide within proSAAS [4].
2. Materials and methods
2.1. Peptide synthesis
Peptide synthesis was performed by Louisiana State University
Health Sciences Center Core Laboratories; mass spectroscopy was
used to verify identity.
2.2. Enzyme assays
The enzyme assays for PC1 and PC2 were performed at pH 5.0 us-
ing pGlu-Arg-Thr-Lys-Arg-methylcoumarinamide (pERTKR-MCA)
(Peptides International, Louisville, KY, USA) as described in [4];
the assay for furin was performed using the same substrate at pH
7.0 in 100 WM HEPES, 5 mM CaCl2 and 0.1% Brij 35. All assays
were performed at 37‡C in a 96 well £uorometer (Labsystems) with an
excitation wavelength of 380 nm and an emission wavelength of
460 nm. When used, inhibitory peptides were preincubated with en-
zyme for 30 min prior to addition of substrate. All assays were per-
formed in duplicate or triplicate. For the determination of IC50’s, the
inhibitor concentration was varied from 1U1034 to 1U10311 M ac-
cording to the method previously described [4]. Ki’s were determined
as previously described [4]. Kinetics were analyzed using EnzFitter
(BioSoft, Cambridge, UK) using Km’s of 11, 42 and 8 WM for PC1,
PC2 and furin, respectively.
2.3. Production of recombinant convertases
Puri¢ed recombinant mouse PC1 and PC2 was obtained from
CHO cells as previously described [4,5]. Recombinant soluble mouse
furin was similarly puri¢ed from the conditioned medium of CHO
cells stably transfected with truncated mouse furin (D108-H771)
and ampli¢ed to 50 WM methotrexate (Cameron et al., in prepara-
tion).
2.4. Cleavage of SAAS Tyr0CT by PC1
SAAS Tyr0CT (residues S219^P258 in intact mouse proSAAS with
the addition of an N-terminal tyrosine) was iodinated by the chlor-
amine T method and puri¢ed by reverse-phase chromatography on a
C-4 column. Iodinated SAAS Tyr0CT (10 000 cpm) was incubated
with 94 ng of PC1 in 50 Wl at 37‡C for varying times. Reaction
products were separated by high-performance liquid chromatography
(HPLC) using a Biosil TSK 125 (Bio-Rad), a Protein Pak 300SW
(Waters) and a TSK A0085 (Bio-Rad) column in series. The £ow
rate was 0.5 ml/min and 0.5 min fractions were collected and counted
by gamma spectroscopy.
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3. Results
3.1. Fragments of SAAS are tight-binding or slow-binding
competitive inhibitors of PC1
We noted that proSAAS contains the precise sequence of a
hexapeptide previously identi¢ed by combinatorial peptide li-
brary screening as a potent inhibitor of PC1 [4]. In order to
verify that the inhibitory activity observed by Fricker et al. [3]
against PC1 was indeed due to this hexapeptide [4], synthetic
peptide fragments of proSAAS were tested against puri¢ed
recombinant mouse PC1, PC2 and furin. We used SAAS
Tyr0CT (corresponding to residues S219^P258 in intact mouse
proSAAS with the addition of an N-terminal tyrosine), SAAS
CT1^24 (corresponding to residues S219^R242 in intact
mouse proSAAS) and the LLRVKR hexapeptide previously
identi¢ed but lacking the terminal blocking groups; sequences
are shown in Fig. 1. As double-reciprocal plots revealed cur-
vature at high substrate and inhibitor concentrations (results
not shown), we established whether or not the SAAS CT
fragments were tight or slow-binding according to the meth-
ods described in [6] and then deduced the nature of the inter-
action between PC1 and the inhibitors. The data in Fig. 2a,c
show that for both SAAS CT1^24 and its C-terminal hexa-
peptide, the IC50 increased with enzyme concentration, a de-
¢ning characteristic of tight and slow-binding reversible inhib-
itors [6,7]. In Fig. 2b,d, the linear increase of IC50 with
substrate concentration demonstrates that both peptides be-
haved as strictly competitive inhibitors.
3.2. Fragments of proSAAS are speci¢c nanomolar inhibitors
of PC1
The Ki’s of the peptides against PC1, PC2 and furin are
shown in Table 1; all were nanomolar inhibitors of PC1 and
exhibited at least two orders of magnitude less inhibitory ac-
tivity against both PC2 and furin. It is interesting to note that
the Ki’s of the SAAS CT fragments against PC1 and PC2
exhibited increased potency with increased peptide length
(i.e. a 3.6- to 3.7-fold decrease in Ki) ; in contrast, the short
hexapeptide was a 24-fold better inhibitor of furin than was
the longer SAAS CT 1^24. In all cases the potency of SAAS
Tyr0CT was less than that of the shorter peptides. When 50 Wg
of SAAS CT1^24 was incubated in the presence of 150 ng of
carboxypeptidase B (Worthington) for 30 min at 37‡C, the
inhibitory action of the peptide against PC1 was abolished.
Fig. 1. Sequence of SAAS CT. The sequence of SAAS CT is
shown; SAAS CT1^24 is underlined. The hexapeptide previously
identi¢ed as a potent inhibitor of PC1 by combinatorial peptide li-
brary screening (4) is double-underlined. The putative cleavage site
is indicated by an arrow.
Fig. 2. E¡ect of enzyme and substrate concentration on the IC50 of proSAAS derived peptides against PC1. IC50’s were determined at varying
enzyme and substrate concentrations using SAAS CT1^24 (a and b) or LLRVKR (c and d). In (a) and (c) the substrate concentration was
¢xed at 200 WM pERTKR-AMC. In (b) and (d) the enzyme concentration was ¢xed at 47 and 94 nM, respectively. All assays were performed
in duplicate at 37‡C in 0.1 M sodium acetate bu¡er, pH 5, 0.1% octyl glucoside and 5 mM calcium chloride. The error bars represent the 95%
con¢dence intervals.
Table 1
Inhibition constants for proSAAS-derived peptides against PC1,
PC2 and furin
Ki (nM) þ S.D.
PC1 PC2 furin
SAAS Tyr0CT 7.4 þ 0.5 10 500 þ 700 6 20 000
SAAS CT1^24 1.5 þ 0.02 990 þ 20 10 000 þ 700
LLRVKR 5.4 þ 0.2 3 700 þ 170 420 þ 14
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3.3. PC1 cleaves SAAS Tyr0CT to produce a fragment with a
mass corresponding to that of the inhibitory sequence
SAAS CT1^24
The 7B2 CT peptide is known to be internally cleaved by
PC2 at a paired basic site ; the resulting peptide remains in-
hibitory until removal of the carboxy-terminal basic residues
by carboxypeptidase action [8]. In order to determine whether
a similar mechanism might hold for PC1/proSAAS, we incu-
bated SAAS Tyr0CT with recombinant PC1 and separated
products by gel permeation HPLC. The data shown in Fig.
3 clearly indicate the production of a smaller PC1-generated
cleavage product that had a mass corresponding to SAAS
CT1^24.
4. Discussion
The ¢rst inhibitor of a member of the family of eukaryotic
subtilisins to be identi¢ed, the neuroendocrine protein 7B2,
contains a carboxy-terminal peptide which represents a nano-
molar tight-binding inhibitor of PC2, with no inhibitory ac-
tivity against the related enzyme PC1 [9,10]. The second neu-
roendocrine convertase inhibitor, proSAAS, was recently
described by Fricker et al. [3]. Our data indicate that the great
majority of the inhibitory activity of proSAAS against PC1 is
borne by a hexapeptide sequence which, like 7B2, is located
within the carboxy-terminal peptide. Interestingly, this precise
hexapeptide was previously identi¢ed by our group in a com-
binatorial peptide library screen of PC1 inhibitors [4]. The
ability of the peptide library screen to predict the sequence
of a naturally occurring protein is remarkable, and demon-
strates the power of combinatorial library screens in the iden-
ti¢cation of natural compounds.
Both SAAS CT-derived peptides and the 7B2 CT peptide
represent very potent inhibitors of convertases, exhibiting
nanomolar Ki’s. The micromolar Ki of a GST^SAAS fusion
protein against PC1 previously obtained [3] may be due to a
destabilizing in£uence of the amino-terminal domain, or to
the use of unpuri¢ed enzyme; these data are di⁄cult to inter-
pret given that the GST moiety alone also appeared to be
inhibitory. Our data also imply that SAAS CT-related pep-
tides may not be as enzyme-speci¢c as the 7B2 CT peptide, as
SAAS-derived CT peptides also exhibited some inhibitory po-
tency against PC2 and, to a lesser extent, against furin. The
inhibition of PC1 and PC2 by SAAS-derived CT peptides
displays a similar response, increasing inhibition, to amino-
terminal extension of the hexapeptide inhibitor, while the
more distantly related enzyme furin is a¡ected oppositely,
suggestive of signi¢cant structural similarities within the bind-
ing pockets of the two neuroendocrine enzymes as opposed to
the constitutively-expressed enzyme furin.
The mechanism of inhibition of PC1 by proSAAS is not yet
clear. Fricker et al. [3], using GST-fusion proteins containing
full-length proSAAS, observed double-reciprocal plots indica-
tive of either tight-binding competitive or of non-competitive
kinetics against PC1. In our hands, SAAS-derived CT pep-
tides were found to exhibit strictly competitive kinetics against
PC1; tight-binding competitive kinetics have also been re-
ported for the inhibition of PC2 by the 7B2 CT peptide [9].
Recent data indicate that inhibition of PC2 by the 7B2 CT
peptide requires two distinct sites within the peptide: the
highly conserved heptapeptide VNPYLQG as well as the
Fig. 3. Cleavage of SAAS Tyr0CT by PC1. Iodinated SAAS
Tyr0CT (10 000 cpm) was incubated at 37‡C with 94 ng PC1 in 50
Wl of 0.1 M sodium acetate bu¡er, pH 5, 0.1% octyl glucoside and
5 mM calcium chloride for 0, 0.5, 1 or 18 h. The reaction products
were separated by HPLC and 0.25 ml fractions counted by gamma
spectroscopy. The column was calibrated using peptides of known
molecular mass with UV detection at 214 nm. The elution volumes
of SAAS Tyr0CT and SAAS CT1^24 are labeled (a) and (b), respec-
tively.
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hexapeptide containing the inhibitory dibasic pair [13]. A
similar two-site mechanism is apparently not required for in-
hibition of PC1 by the SAAS CT peptide, as the hexapeptide
containing the dibasic pair is a highly potent inhibitor in its
own right. Despite these di¡erences, our data indicate that
both the SAAS and the 7B2 CT peptides represent nanomolar
inhibitors of PCs and are thus likely to function in the phys-
iological control of convertase activity within the secretory
pathway.
Inactivation of the 7B2 CT peptide is thought to be accom-
plished by PC2-mediated hydrolysis at the inhibitory dibasic
pair, followed by carboxypeptidase action [8]. Our data indi-
cate that a similar mechanism might hold for the inactivation
of the SAAS CT peptide by PC1, as iodinated SAAS CT
peptide was e⁄ciently cleaved by PC1 in vitro to yield a pep-
tide product with a mass corresponding to that of SAAS
CT1^24. In addition, incubation of SAAS CT1^24 with car-
boxypeptidase B abolished inhibitory potency. While further
work will be required to establish that cleavage of SAAS CT
is indeed speci¢c to PC1 in vivo, the ability of PC1 to accom-
plish this cleavage in vitro lends credence to the idea that
inactivation of the two CT peptides might occur similarly.
While the primary sequences of 7B2 and proSAAS are not
homologous, the overall structures of these two proteins ex-
hibit a striking resemblance, with the inhibitory sequences
located at the carboxyl terminus following a furin consensus
sequence (RXXR). Further, proSAAS contains many con-
served proline residues located in the middle of the protein,
a feature and location reminiscent of the proline-rich sequence
(PPNPCP) present in all known 7B2s [11] which is known to
be absolutely required for biological activity [12]. While it is
di⁄cult to search for proline-rich sequences in the database
due to their relatively high abundance, we speculate that as-
yet-to-be discovered inhibitors of other members of the verte-
brate convertase family will exhibit the same elements of
structural homology as do proSAAS and 7B2: a proline-
rich sequence in the middle of the protein; a furin consensus
site approximately 30^40 residues from the carboxyl terminus
and a carboxyl-terminal peptide containing a potent inhibi-
tory sequence.
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